Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to sales

×

Great! We'll call you.

×

×

Send an email to us

×

Pioneer Life Sciences EIS Knowledge Intensive Fund

Invest in a balanced portfolio of early-stage life science businesses.

At a glance
  • Current status: Closed
  • Fund type: EIS Knowledge Intensive
  • Investment goal: Capital growth

  • Focus: Life sciences
  • Target returns: 30% IRR
  • Target holding period: 7 years

  • Minimum subscription: £25,000
Invest now

The objective of the Fund is to invest in a balanced portfolio of early-stage life science businesses with the aim of generating an excellent return for Investors. By doing this we will help to create and grow some exciting, innovative and potentially life changing companies. The businesses the Fund will invest in may have an impact on their local economy, providing highly skilled jobs and further increasing the overall strength of the UK life sciences sector.

Investment selection process

A team of venture builders and WAPG’s network of science infrastructure across the UK provide privileged access to a stream of validated investment opportunities. Our sites and venture development activity act as funnels, drawing in the best opportunities in the area.

WAPG will be working with opportunities from various sources including ICURe, Oxford and East Midlands AHSN Accelerators, Scottish University Accelerator, Scottish Universities Accelerator, Scottish High Growth Programme, Pharma Partners, WAPG's own network.

EIS tax incentives
The companies the fund invest in are expected to be EIS & Knowledge Intensive (KI)-qualifying, which makesPioneer Life Sciences Knowledge Intensive EIS Fund EIS-KI suitable for qualifying clients who would potentially benefit from the following tax reliefs:
  • Up to 30% income tax relief (As the fund is knowledge-intensive you can choose to carry back income tax relief to the previous tax year or in the tax year that the Fund closes)
  • Tax-free investment growth
  • Capital gains deferral
  • Inheritance tax relief
  • Loss relief
Please note: EIS tax reliefs are only made available to investors because of the higher risks associated with investing in early-stage companies. Also, the availability of tax reliefs will depend on the investor's personal circumstances, and tax legislation can change in the future.
Fund team

Example of fund team's previous investments

BiVitrix Therapeutics

Founded in 2016, and derived from frontline clinical experience, BiVictriX is a rapidly emerging biotechnology company applying a novel approach to develop safer, more effective cancer therapies.

XenoGesis

Based at BioCity Nottingham, XenoGesis specialises in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology, DMPK due diligence and modelling and simulation, and has worked directly on the predictions of human PK and dose for eight compounds that have entered clinics.

roylance-pharma

Roylance Pharma is a provider of biobanking and stability storage facilities to store pharmaceutical and biological samples.

Next Slide
prev
next
Want more information?

Book a consultation with one of our team

Explore other investments
Important information
To invest, you must be an eligible investor. To be an eligible investor, you must be qualifying as one or more of the following:
  • You meet the FCA’s definition of a professional investor.
  • You meet the FCA’s definition of a certified high net worth investor.
  • You meet the FCA’s definition of a self-certified sophisticated investor.
  • You meet the FCA’s definition of a self-certified restricted investor.
  • You are a client of an FCA authorised firm that will provide advice on the suitability of the product in question.
 
Risk warning
Important information for private investors – Reliance on the information provided here to engage in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. Your attention is drawn to the risk section contained within the Information Memorandum. Investments are typically in unquoted shares in small companies, the value of which can be volatile and are often difficult to sell. Nothing on this website constitutes investment, tax, financial, legal, regulatory, or other advice by Sapphire Capital Partners LLP.
The value of an investment may go down as well as up, and you may not get back the full amount invested, and you may therefore lose some or all of your investment.
If you are unsure of the suitability of any investment for your circumstances, please contact your independent financial advisor or other professional advisor authorised under the Financial Services and Markets Act 2000 (FSMA) who specialises in advising on investments of this type. Tax reliefs depend on individual circumstances. There is no guarantee however that the tax reliefs (such as SEIS and/or EIS reliefs, CGT reliefs or IHT relief) will be available on any investment made or that if it is initially available, it will not be subsequently withdrawn. Any references to tax laws or rates are based on current legislation, all of which are subject to change and are provided as a guide only. Prospective investors are advised to obtain their own investment and taxation advice and should consult their own professional advisors on the implications of investing.
Investments made in investee companies via funds managed by Sapphire Capital Partners LLP may not be covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk
Past performance is not a guide to future returns. CAPITAL AT RISK. 

Get in touch

We are here to help you get started.